Chemotherapy for Osteosarcoma without High-Dose Methotrexate: Another Piece in the Puzzle-Reference-Cited by-同舟云学术

Chemotherapy for Osteosarcoma without High-Dose Methotrexate: Another Piece in the Puzzle

Published:2007 Issue:5 Volume:30 Page:226-227
ISSN:2296-5270
Container-title:Oncology Research and Treatment
language:en
Short-container-title:Oncol Res Treat

Author:

Blay Jean-Yves

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,Hematology

Reference17 articles.

1. Link MP, Meyers PA, Gebhardt M: Osteosarcoma; in Pizzo PA, Poplack DG (eds): Principles and Practices of Pediatric Oncology, 4th ed. Philadelphia, Lippincott Williams and Wilkins, 2001, pp 1061-1069.

2. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study.

3. The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity

4. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response.

5. Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A genome-wide expression profile of noncoding RNAs in human osteosarcoma cells as they acquire resistance to cisplatin;Discover Oncology;2021-10-20

2. Methotrexate–Etoposide–Ifosfamide Compared with Doxorubicin–Cisplatin–Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18–25 Years;Journal of Adolescent and Young Adult Oncology;2020-04-01

3. Results of API–AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome‐09 study;International Journal of Cancer;2019-07-19

4. The dynamic role of autophagy and MAPK signaling in determining cell fate under cisplatin stress in osteosarcoma cells;PLOS ONE;2017-06-09

5. Analysis of Chemotherapy Dosage and Dosage Intensity and Survival Outcomes of High-Grade Osteosarcoma Patients Younger Than 40 Years;Clinical Therapeutics;2014-04